GlassScriptPhysician profile
Eiko T Browning
NPI 1215083811
$3,349.09
in general payments reported to CMS, 2019-2025
48 companies · $1,805 in 2025
The $1,805 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.76 · 2021: $154 · 2022: $95.87 · 2023: $245 · 2024: $1,022 · 2025: $1,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,993 · Education: $78.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,993.41 |
| Education | $78.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $202.21 | 2022-2024 | Mychoice Cdx, Myrisk |
| Astellas Pharma US INC | $201.27 | 2024-2025 | Vyloy, Padcev |
| Genentech USA, INC. | $197.43 | 2022-2025 | Venclexta, Tecentriq, Polivy |
| E.R. Squibb & Sons, L.L.C. | $195.73 | 2021-2025 | Opdivo |
| Tersera Therapeutics LLC | $146.08 | 2023-2025 | Xermelo, Zoladex |
| Stemline Therapeutics INC. | $139.73 | 2023-2025 | Orserdu |
| Exelixis INC. | $136.76 | 2024-2025 | Cabometyx |
| Abbvie INC. | $123.63 | 2024-2025 | |
| Sobi, INC | $117.87 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $116.18 | 2024-2025 | Keytruda, Welireg |
| Novartis Pharmaceuticals Corporation | $108.03 | 2024-2025 | |
| Emd Serono, INC. | $107.29 | 2024-2025 | |
| Gilead Sciences, INC. | $105.06 | 2021-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $86.89 | 2024-2025 | |
| Eisai INC. | $83.33 | 2024-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $81.10 | 2024-2025 | Onivyde |
| Puma Biotechnology, INC. | $76.75 | 2024-2025 | |
| Daiichi Sankyo INC. | $74.09 | 2025 | Enhertu, Datroway |
| Celgene Corporation | $71.14 | 2024 | Reblozyl |
| Sumitomo Pharma America, INC. | $64.69 | 2023-2024 | Orgovyx |
| Pfizer INC. | $63.89 | 2023-2025 | |
| Janssen Biotech, INC. | $57.94 | 2022-2024 | Erleada, Akeega, Balversa |
| Takeda Pharmaceuticals U.S.A., INC. | $56.94 | 2024-2025 | Iclusig |
| Astrazeneca Pharmaceuticals LP | $56.78 | 2019-2025 | Imfinzi |
| Glaxosmithkline, LLC. | $55.53 | 2025 | Ojjaara, Jemperli, Zejula |
| Genentech, INC. | $53.45 | 2024 | Tecentriq |
| Genzyme Corporation | $46.44 | 2025 | |
| Iovance Biotherapeutics, INC. | $40.81 | 2025 | Amtagvi |
| Regeneron Healthcare Solutions, INC. | $35.19 | 2025 | Libtayo |
| Caris Mpi, INC. | $33.90 | 2025 | Mi Cancer Seek |
| Jazz Pharmaceuticals INC. | $31.79 | 2023 | |
| Azurity Pharmaceuticals, INC. | $28.72 | 2025 | Danziten |
| Tempus Ai, INC | $28.15 | 2024 | |
| Incyte Corporation | $27.91 | 2025 | Jakafi, Niktimvo |
| Taiho Oncology, INC. | $26.67 | 2024 | |
| Nuvation Bio INC. | $25.30 | 2025 | Ibtrozi |
| Genmab U.S., INC. | $24.20 | 2025 | Epkinly |
| Seagen INC. | $24.14 | 2023 | Padcev |
| Recordati_rare_diseases_inc. | $24.14 | 2025 | Enjaymo |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Rigel Pharmaceuticals, INC. | $22.20 | 2025 | Tavalisse, Gavreto, Rezlidhia |
| Alexion Pharmaceuticals, INC. | $21.41 | 2024 | Ultomiris |
| Mirati Therapeutics, INC. | $20.91 | 2024 | Krazati |
| Kyowa Kirin, INC. | $19.61 | 2025 | |
| Medtronic, INC. | $19.42 | 2024 | Osteocool Rf Ablation System |
| Pharmacosmos Therapeutics INC. | $17.62 | 2025 | Monoferric |
| Novocure INC. | $14.36 | 2025 | Optune Gio |
| Medtronic USA, INC. | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eiko Browning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.